Collegium posts record Q3 revenue $159.3M, up 17%; names Vikram Karnani CEO

COLLEGIUM PHARMACEUTICAL, INC

2024-Q3 EPS reported $1.51 revenue$449,500,000

Q3 net revenue $159.3M (record), up 17% YoY; GAAP net income $9.3M ($0.27 diluted EPS).
Adjusted EBITDA $105.1M, up 18% YoY; non-GAAP adjusted EPS $1.61.
Reaffirms FY2024 guidance: product revenue $620-635M, adjusted EBITDA $395-405M.
Appoints Vikram Karnani as President and CEO effective Nov 12, 2024; Heffernan remains Chairman.
Closed Ironshore acquisition (Jornay PM) in Sep 2024, entering ADHD neurology.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vikram Karnani

President and Chief Executive Officer

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2024-11-12
Filed: November 7, 2024, 6:59 PM ET

the Board of Directors (the “Board”) of the Company appointed Vikram Karnani to serve as the Company’s President and Chief Executive Officer, effective November 12, 2024

Appointed

Vikram Karnani

member of the Board

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2024-11-12
Filed: November 7, 2024, 6:59 PM ET

Concurrently with his appointment as President and Chief Executive Officer and effective as of the Effective Date, Mr. Karnani will be appointed to serve as a member of the Board

Role change

Michael Heffernan

President and Chief Executive Officer

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2024-11-12
Successor: Vikram Karnani
Filed: November 7, 2024, 6:59 PM ET

succeeding Michael Heffernan, who will continue to serve as the Company’s Chairman of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Vikram Karnani was appointed as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Board of Directors (the “Board”) of the Company appointed Vikram Karnani to serve as the Company’s President and Chief Executive Officer, effective November 12, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Vikram Karnani was appointed as member of the Board at COLLEGIUM PHARMACEUTICAL, INC.

Action: appointed
Role: member of the Board

Exact text from the filing

Concurrently with his appointment as President and Chief Executive Officer and effective as of the Effective Date, Mr. Karnani will be appointed to serve as a member of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Heffernan changed role as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.

Action: succeeded
Role: President and Chief Executive Officer

Exact text from the filing

succeeding Michael Heffernan, who will continue to serve as the Company’s Chairman of the Board.

View on SEC.gov

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001104659-24-115287

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.